These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1571213)

  • 1. Iphosphamide-induced nephrotoxicity in children.
    Shore R; Greenberg M; Geary D; Koren G
    Pediatr Nephrol; 1992 Mar; 6(2):162-5. PubMed ID: 1571213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
    J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
    Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors.
    Loebstein R; Koren G
    Pediatrics; 1998 Jun; 101(6):E8. PubMed ID: 9606250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
    Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
    Suarez A; McDowell H; Niaudet P; Comoy E; Flamant F
    J Clin Oncol; 1991 Dec; 9(12):2177-82. PubMed ID: 1720453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide nephrotoxicity in pediatric cancer patients.
    Lee BS; Lee JH; Kang HG; Hahn H; Lee JH; Shin HY; Ha IS; Cheong HI; Ahn HS; Choi Y
    Pediatr Nephrol; 2001 Oct; 16(10):796-9. PubMed ID: 11605785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of age on nephrotoxicity following chemotherapy in children.
    Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
    Br J Cancer Suppl; 1992 Aug; 18():S30-5. PubMed ID: 1503924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function abnormalities after ifosfamide treatment in children.
    De Schepper J; Hachimi-Idrissi S; Verboven M; Piepsz A; Otten J
    Acta Paediatr; 1993 Apr; 82(4):373-6. PubMed ID: 8318805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for ifosfamide nephrotoxicity in children.
    Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
    Lancet; 1996 Aug; 348(9027):578-80. PubMed ID: 8774570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal toxicity and chemotherapy in children with cancer.
    Ruggiero A; Ferrara P; Attinà G; Rizzo D; Riccardi R
    Br J Clin Pharmacol; 2017 Dec; 83(12):2605-2614. PubMed ID: 28758697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesna excretion and ifosfamide nephrotoxicity in children.
    Goren MP; Pratt CB; Meyer WH; Wright RK; Dodge RK; Viar MJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7153-7. PubMed ID: 2510931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biochemical parameters in the diagnosis of nephrotoxicity of antineoplastic chemotherapy in children].
    Liubimova NV; Kumykova ZhKh; Kushlinskiĭ NE; Kasumov ChM; Durnov LA
    Vopr Onkol; 1997; 43(4):448-53. PubMed ID: 9381703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
    Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
    Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide nephrotoxicity in children: histopathological features in two cases.
    Morland BJ; Mann JR; Milford DV; Raafat F; Stevens MC
    Med Pediatr Oncol; 1996 Jul; 27(1):57-61. PubMed ID: 8614393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide in pediatric oncology.
    Voûte PA; de Kraker J
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):2-6. PubMed ID: 1411617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
    Rossi R; Gödde A; Kleinebrand A; Riepenhausen M; Boos J; Ritter J; Jürgens H
    J Clin Oncol; 1994 Jan; 12(1):159-65. PubMed ID: 8270973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth impairment after ifosfamide-induced nephrotoxicity in children.
    Stöhr W; Patzer L; Paulides M; Kremers A; Beck JD; Langer T; Rossi R
    Pediatr Blood Cancer; 2007 May; 48(5):571-6. PubMed ID: 16755549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal dysfunctions secondary to ifosfamide treatment in children.
    Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
    J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.